{"product_id":"zynex-bcg-matrix","title":"Zynex Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZynex’s BCG Matrix preview highlights key products across growth and market-share dimensions, showing which offerings are potential Stars or aging Cash Cows and which may be Dogs or Question Marks needing strategic decisions. The full BCG Matrix provides quadrant-level data, competitor context, and actionable recommendations to optimize portfolio allocation and capital deployment. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary—fast, data-driven guidance to inform investment and product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexWave Device Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe NexWave is Zynex’s flagship electrotherapy device, holding an estimated 22% share of the non-invasive pain management market and driving roughly $112M in 2025 revenue, as demand shifts from opioids to multimodal care.\u003c\/p\u003e\n\u003cp\u003eIt integrates TENS (transcutaneous electrical nerve stimulation), IFC (interferential current), and NMES (neuromuscular electrical stimulation), giving clinical versatility and supporting a 14% CAGR in device sales since 2022.\u003c\/p\u003e\n\u003cp\u003eTo stay a BCG Star, Zynex needs continued investment: planned 2026 sales-force expansion (up 18%) and $6.5M in physician education programs to protect share and extend adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Operative Recovery Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex’s post-operative recovery devices are Stars: they hold ~35–45% share in specialized orthopedic clinics and drove ~28% of product revenue in 2024, as demand for non-pharmacological recovery tools rose with ~6–8% annual surgical volume growth through 2025.\u003c\/p\u003e\n\u003cp\u003eThese solutions require heavy capital for distribution and clinical training, with estimated FY2024 SG\u0026amp;A allocation to this segment near $12–15M and capex-backed pilots in 2024–25 totaling ~$4–6M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Patient Distribution Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex’s proprietary direct-to-patient distribution and billing platform creates a strong moat, supporting 2025 home-care revenues of $198M and a 42% market share in US remote therapeutic devices.\u003c\/p\u003e\n\u003cp\u003eThe model enables rapid scaling of new devices—launch cadence rose 60% from 2022–2025—but requires heavy cash for claims processing and compliance, with SG\u0026amp;A rising to 28% of sales in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex’s push into Europe and Asia for its electrotherapy line targets \u0026gt;15% CAGR regional growth; initial 2025 sales were ~$6.2M, market share rising from 0.5% to ~1.8%, marking a Star in the BCG matrix due to high growth and growing share.\u003c\/p\u003e\n\u003cp\u003eThese markets need localized marketing and CE\/PMDA\/CFDA-style approvals, driving high cash burn—estimated $10–14M in 2024–25 combined capex and operating expenses for rollout.\u003c\/p\u003e\n\u003cp\u003eIf approvals and adoption hold, regions should become Cash Cows within 3–5 years as global demand for non-opioid pain management (projected $8.6B global TAM by 2027) matures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 sales ~ $6.2M\u003c\/li\u003e\n\u003cli\u003eRegional share ~1.8%\u003c\/li\u003e\n\u003cli\u003eEstimated rollout cash burn $10–14M (2024–25)\u003c\/li\u003e\n\u003cli\u003eTime to Cash Cow 3–5 years\u003c\/li\u003e\n\u003cli\u003eGlobal non-opioid pain TAM $8.6B by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Neuromuscular Rehabilitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNext-Generation Neuromuscular Rehabilitation products, focused on stroke recovery and neurological rehab, have captured a dominant niche with estimated 35% market share in the US neuro-physiotherapy segment as of 2025 and revenue growth of ~48% CAGR since 2022.\u003c\/p\u003e\n\u003cp\u003eThese offerings sit squarely in the BCG Stars quadrant: high growth (market expansion \u0026gt;25% annual) and high relative share, requiring ongoing R\u0026amp;D spend—Zynex invested $12.4M in 2024 R\u0026amp;D for neuro devices—to fend off new entrants.\u003c\/p\u003e\n\u003cp\u003eThey underpin Zynex’s clinical future, offering high revenue potential but carrying elevated operational costs (manufacturing, clinical trials, training), with gross margins around 42% in FY2024 and projected margin pressure if R\u0026amp;D rises above 15% of sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share ~35% (US neuro-physio, 2025)\u003c\/li\u003e\n\u003cli\u003eRevenue growth ~48% CAGR (2022–2025)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend $12.4M (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin ~42% (FY2024)\u003c\/li\u003e\n\u003cli\u003eHigh growth, high-cost Star requiring sustained investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex Triple-Play Poised for $198M Home-Care by 2025; Regions Cash Cows in 3–5 yrs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex Stars: NexWave (22% share, $112M 2025), post-op devices (35–45% clinic share, 28% 2024 revenue), neuro rehab (35% US share, 48% CAGR 2022–25); combined 2025 home-care $198M; 2024–25 rollout\/R\u0026amp;D spend ~$34–38M; regions to Cash Cow in 3–5 years if approvals hold.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003e2025 $\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexWave\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003e$112M\u003c\/td\u003e\n\u003ctd\u003e14% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-op\u003c\/td\u003e\n\u003ctd\u003e35–45%\u003c\/td\u003e\n\u003ctd\u003e28% rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$12–15M SG\u0026amp;A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuro\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e48% CAGR; $12.4M R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Zynex products with strategic recommendations for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Zynex BCG Matrix placing each product in a quadrant for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexWave Consumable Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy 2025 NexWave consumables—electrodes and batteries—deliver steady, high-margin cash: recurring sales hit roughly $42M annual revenue, with gross margins near 65% and a market share ~60% in rehab electrodes.\u003c\/p\u003e\n\u003cp\u003eWith an installed base exceeding 120,000 NexWave units by Dec 2025, marketing spend is minimal (\u0026lt;3% of segment revenue), keeping operating costs low.\u003c\/p\u003e\n\u003cp\u003eThat excess cash funded R\u0026amp;D and acquisitions, contributing about $18M in free cash flow to Zynex’s expansion into new medical technologies in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Pain Management Renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-term patients using Zynex neurostimulation and TENS devices form a stable, low-growth cash cow: recurring rentals and renewals accounted for about 55% of Zynex's 2024 device revenue (≈$38M), reflecting high retention and predictable demand.\u003c\/p\u003e\n\u003cp\u003eMaintaining these accounts needs minimal capital—replacement parts and logistics—yielding gross margins near 63% in 2024 and steady operating cash flow that funds interest on ~ $15M net debt (FY2024) and supports $5–7M annual R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy TENS Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy TENS units—basic electrotherapy devices—hold about 35% of Zynex’s product revenue and dominate the value-driven segment, with global TENS market growth near 2% CAGR (2020–2025) signaling plateaued demand.\u003c\/p\u003e\n\u003cp\u003eManufacturing is mature: gross margins ~58% on legacy units due to optimized processes and per-unit cost down 12% since 2022, keeping contribution margins high.\u003c\/p\u003e\n\u003cp\u003eThese products generate steady EBIT contribution with minimal marketing spend—operating expenses for legacy TENS under 6% of segment revenue—making them cash cows in Zynex’s BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Billing and Collection Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex’s mature billing and collections for durable medical equipment (DME) delivers steady cash: in 2024 collections covered ~62% of operating cash inflows, reflecting specialized staff, payer contracts, and denial-management processes that cut days sales outstanding to ~38 days.\u003c\/p\u003e\n\u003cp\u003eThat efficient infrastructure funds R\u0026amp;D and newer units, supports margins (gross margin +8pp vs peers in 2024), and stabilizes cashflows amid episodic device cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 collections ≈62% of operating cash\u003c\/li\u003e\n\u003cli\u003eDSO ≈38 days (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin +8 percentage points vs peers\u003c\/li\u003e\n\u003cli\u003eFunds R\u0026amp;D and volatile units\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Clinical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMature partnerships with major physical therapy chains and hospital networks deliver steady bulk placements for Zynex, supporting roughly 18–22% of device revenue in 2024 and showing low incremental cost per unit due to established procurement pipelines.\u003c\/p\u003e\n\u003cp\u003eThese contracts, often multi-year and renewal-prone, yield high market share within partner networks and predictable cash flows that underwrite R\u0026amp;D and market-expansion spends while reducing revenue volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 device revenue contribution: 18–22%\u003c\/li\u003e\n\u003cli\u003eLow incremental cost: \u0026lt; $50 per unit estimate within contracts\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts: renewal rates \u0026gt; 80% in partner pools\u003c\/li\u003e\n\u003cli\u003eSupports funding for R\u0026amp;D and commercial expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex cash cows: $80–82M revenue, 58–65% gross, $18M FCF, $15M net debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex cash cows: NexWave consumables and legacy TENS\/recurring rentals generate ~ $80–82M revenue (2024–2025), gross margins 58–65%, free cash flow ~ $18M (2025), DSO ~38 days, collections ~62% of operating cash, partner-driven device revenue 18–22% (2024), funding $5–7M R\u0026amp;D and servicing ~$15M net debt.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (cash cows)\u003c\/td\u003e\n\u003ctd\u003e$80–82M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e58–65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow (2025)\u003c\/td\u003e\n\u003ctd\u003e$18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDSO (2024)\u003c\/td\u003e\n\u003ctd\u003e38 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollections share\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner device rev\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D funded\u003c\/td\u003e\n\u003ctd\u003e$5–7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eZynex BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—fully formatted and ready for presentation. This preview mirrors the final downloadable document, crafted with clear positioning, market-backed inputs, and strategic annotations so you can use it immediately. Upon purchase the full, editable file is delivered to your inbox with no surprises, perfect for client briefs, board decks, or internal planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748244697465,"sku":"zynex-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zynex-bcg-matrix.png?v=1772206420","url":"https:\/\/matrixbcg.com\/products\/zynex-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}